Behcet's Disease - Pipeline Review, H2 2012

Global Markets Direct, September 2012, Pages: 55

Behcet's Disease – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Behcet's Disease - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Behcet's Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Behcet's Disease. Behcet's Disease - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Behcet's Disease.
- A review of the Behcet's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Behcet's Disease pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Behcet's Disease.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Behcet's Disease pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Behcet's Disease Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Behcet's Disease 7
Behcet's Disease Therapeutics under Development by Companies 9
Behcet's Disease Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Pre-Clinical Stage Products 14
Comparative Analysis 14
Behcet's Disease Therapeutics – Products under Development by Companies 15
Behcet's Disease Therapeutics – Products under Investigation by Universities/Institutes 16
Companies Involved in Behcet's Disease Therapeutics Development 17
Johnson & Johnson 17
Abbott Laboratories 18
Celgene Corporation 19
XOMA Ltd. 20
CREABILIS Therapeutics S.r.l. 21
Behcet's Disease – Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Combination Products 23
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
apremilast - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
adalimumab - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
infliximab - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
gevokizumab - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Cyclophosphamide + Anti-thymocyte Globulin + Hematopoietic Stem Cell Transplantation - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
interferon alpha-2a - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
CT-335 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Behcet's Disease Therapeutics – Drug Profile Updates 39
Behcet's Disease Therapeutics – Discontinued Products 52
Behcet's Disease Therapeutics - Dormant Products 53
Appendix 54
Methodology 54
Coverage 54
Secondary Research 54
Primary Research 54
Expert Panel Validation 54
Contact Us 55
Disclaimer 55

List of Tables
Number of Products Under Development for Behcet's Disease, H2 2012 7
Products under Development for Behcet's Disease – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Early Clinical Stage Development, H2 2012 13
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Investigation by Universities/Institutes, H2 2012 16
Johnson & Johnson, H2 2012 17
Abbott Laboratories, H2 2012 18
Celgene Corporation, H2 2012 19
XOMA Ltd., H2 2012 20
CREABILIS Therapeutics S.r.l., H2 2012 21
Assessment by Monotherapy Products, H2 2012 22
Assessment by Combination Products, H2 2012 23
Assessment by Stage and Route of Administration, H2 2012 25
Assessment by Stage and Molecule Type, H2 2012 27
Behcet's Disease Therapeutics – Drug Profile Updates 39
Behcet's Disease Therapeutics – Discontinued Products 52
Behcet's Disease Therapeutics – Dormant Products 53

List of Figures
Number of Products under Development for Behcet's Disease, H2 2012 7
Products under Development for Behcet's Disease – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Early Clinical Stage Products, H2 2012 13
Pre-Clinical Stage Products, H2 2012 14
Assessment by Monotherapy Products, H2 2012 22
Assessment by Combination Products, H2 2012 23
Assessment by Route of Administration, H2 2012 24
Assessment by Stage and Route of Administration, H2 2012 25
Assessment by Molecule Type, H2 2012 26
Assessment by Stage and Molecule Type, H2 2012 27

Customers who bought this item also bought

• Acute Pain - Pipeline Review, H2 2012
• Psoriasis - Pipeline Review, H2 2012
• Other Immunological Disorders - Pipeline Review, H2 2012
• Smoking Cessation - Pipeline Review, H2 2012
• Rheumatoid Arthritis - Pipeline Review, H2 2012
• Obesity - Pipeline Review, H2 2012
• Ocular Inflammation - Pipeline Review, H2 2012
• Male Cancer - Pipeline Review, H2 2012
• Autoimmune Disorders - Pipeline Review, H2 2012
• Osteoarthritis - Pipeline Review, H2 2012